20:57:02 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-05 Kvartalsrapport 2024-Q3
2024-08-06 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2024-04-29 Ordinarie utdelning CRBX 0.00 SEK
2024-04-26 Årsstämma 2024
2024-02-16 Bokslutskommuniké 2023
2024-01-10 Extra Bolagsstämma 2024
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-08 Kvartalsrapport 2023-Q2
2023-05-09 Kvartalsrapport 2023-Q1
2023-04-24 Ordinarie utdelning CRBX 0.00 SEK
2023-04-21 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-08 Kvartalsrapport 2022-Q3
2022-08-09 Kvartalsrapport 2022-Q2
2022-05-10 Kvartalsrapport 2022-Q1
2022-04-25 Ordinarie utdelning CRBX 0.00 SEK
2022-04-22 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-10 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-04-26 Ordinarie utdelning CRBX 0.00 SEK
2021-04-23 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-11 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-27 Ordinarie utdelning CRBX 0.00 SEK
2020-04-24 Årsstämma 2020
2020-02-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
Carbiotix är ett bioteknikföretag verksamma inom mikrobiomområdet. Företaget bedriver idag forskning och utveckling samt säljer produkter och tjänster inom primärt fyra affärsområden: Diagnostik av tarmhälsa, prebiotiska ingredienser, medicinsk mat och terapeutiska behandlingar. Bolaget grundades under 2014 och har sitt huvudkontor i Lund.
2024-04-04 11:00:00

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has commenced a pilot study with the same leading US food & beverage producer mentioned in a March 6th press release. The pilot study is the second step in the NutraCycle Pre-Study and commences only after a successful laboratory study. In this case, the laboratory study verified both a viable process and upcycled Carbersol prebiotic ingredient that also has the potential to replace sugars, texturizers and provide other health benefits. The pilot study will validate the process and Carbersol prebiotic ingredient developed at pilot-scale and will be carried out over the next two months with the goal of entering the NutraCycle Joint Development phase.

Erik Deaner, CEO of Carbiotix, comments:
"I am very happy to announce that Carbiotix has commenced the pilot study step of the NutraCycle PreStudy with a leading US food & beverage producer. The company in question, mentioned in a press release on the 6th of March, has a turnover exceeding 2 billion USD and is a leader in their respective segment both in terms of geographic presence and market share. The NutraCycle service can however be leveraged by all food & beverage and ingredient producers globally that process plant-based raw materials and generate side stream products that could be upcycled into prebiotic ingredients.

The benefits of the NutraCycle service for food & beverage and ingredient companies are severalfold. It is a relatively low cost and low risk approach to generating new revenue streams and achieving higher pricing power for existing products. For example, it is an opportunity to upcycle side stream products into high value Carbersol prebiotics that can be used to fortify existing products, develop new products, and be sold as an ingredient, as well increase the relative protein content and value of residuals. These Carbersol prebiotics can also reduce the need for added sugars and texturizers and in some cases provide additional health benefits.

The pilot study is the second step in the NutraCycle Pre-Study to determine if a side-stream product can be upcycled into a prebiotic that can be primarily utilized in the fortification of new and existing products. The pilot study only commences upon the completion of a successful laboratory study, with both steps completed typically over a 3-month period. Successful Pre-Studies lead to NutraCycle Joint Development Agreements between Carbiotix and a plant-based food & beverage or ingredient producer. At this stage, Carbiotix provides support with regards to process design - based upon Carbiotix IP and trade secret, product formulation and development, scientific validation and regulations, and technology partner building. Once a Carbersol process has been built, Carbiotix provides continued support with regards to operations, process optimization, product development and customer leads through a royalty and service agreement.

I look forward to completing the pilot study step of the NutraCycle Pre-Study and potentially commencing with the Joint Development Phase in the coming months. This rapid development is testimony of both the interest and potential of the NutraCycle service. There are many plant-based based food & beverage and ingredient manufactures in the world who could benefit from the NutraCycle service, and we will continue to ramp up on-line and in-person marketing activities during 2024 to showcase this."

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on 4 April 2024.

Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:
Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.